ChromaDex Corp. (CDXC.OB) Receives “Most Promising Ingredient of the Year” Award from Frost & Sullivan for pTeroPure Pterostilbene

By @ibtimes on

ChromaDex, www.chromadex.com – the life sciences company offering proprietary, science-based ingredients and solutions to the dietary supplement, food, beverage, cosmetic and pharmaceutical industries, reported today that the Company has been awarded 2010 North American Health Ingredients Most Promising Ingredient of the Year for its proprietary pTeroPure™ Pterostilbene branded ingredient.

The award was conferred by acclaimed independent research company Frost & Sullivan, who benchmarked ChromaDex against competing companies as part of the decision, based on a strict criterion incorporating the unique selling features, ongoing commitment to research, existing market penetration and growth potential, as well as marketing and promotional undertakings engaged in.

CEO of CDXC, Frank Jaksch, called this award a clear endorsement of the true market potential of pTeroPure and of ChromaDex, citing pTeroPure’s ability “to produce sustained value across multiple market channels” by providing scientifically quantified health benefits to a wide range of consumer segments.

The humble blueberry naturally produces the pterostilbene compound as a means of warding off and fighting infection from various forms of bacteria and fungi. This compound is from the phytoalexin group which has been shown in several published studies to markedly combat diabetes, high blood pressure and cholesterol levels, oxidative stresses and the neurodegeneration associated with a host of neurological disorders/diseases.

Senior research analyst at Frost & Sullivan, Sneha Pasricha, noted the key intellectual property position of CDXC and rapidly accruing awareness about the highly beneficial properties of pterostilbene, which has massive market potential in the human nutrition industry.

Two patents pending have been licensed by CDXC from the USDA via the University of Mississippi, one process patents generated by a manufacturing partner and another through a collaborative effort with the University of California at Irvine. The first patent hinges on pterostilbene lowering blood lipoprotein levels via PPAR-alpha activation (peroxisome proliferator-activated receptor) and the second on the compound’s ameliorative effect on oxidative stress, as well as the compound’s cognitive/memory boosting properties.

The potential of pterostilbene is clear and CDXC has devised a strategy to take full advantage with an expanded patent portfolio through additional filings, as new categories for the compound emerge from technical progress.

A study designed to yield further meaningful data regarding the effects of pterostilbene in patients suffering from cholesterol and blood pressure problems is currently underway at the University of Mississippi. This study will help advance the profile of pterostilbene, strengthening CDXC’s already solid intellectual property footing ahead of anticipated expansion into additional health markets like anti-aging, heart health and memory enhancement.

Join the Discussion